NeuroPace Shares Surge 6.3% to $18.12 on Heavy Volume, Q1 Revenue Seen $21.6M
NeuroPace shares jumped 6.3% to $18.12 on trading volume well above the four-week average, extending a 17.4% gain over that period. Consensus projects first-quarter revenue of $21.6 million and a loss of $0.19 per share, with no estimate revisions in the past 30 days.
1. Recent Trading Surge
NeuroPace shares climbed 6.3% to close at $18.12 in the last session, with trading volume significantly above the four-week average. This move extends a 17.4% gain over the past month and highlights heightened investor interest ahead of the first-quarter report.
2. First-Quarter Financial Outlook
The consensus forecast for Q1 calls for $21.6 million in revenue, down 4% year-over-year, and a net loss of $0.19 per share, a 9.5% widening from the year-ago quarter. The company is scheduled to release results on May 12, making these metrics key to post-report price action.
3. Estimate Stability and Outlook
Analyst estimates for earnings per share have remained unchanged over the last 30 days, suggesting limited revision-driven momentum. The stock carries a #3 (Hold) rating within the medical instruments industry, indicating a cautious stance pending actual Q1 results.